Last reviewed · How we verify
NCT02958384
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
Phase 1/Phase 2 trial testing Anti-LeY-CAR-transduced T cells in Myeloid Malignancies in 45 participants. Status unknown.
1 October 2019
Quick facts
| Lead sponsor | Southwest Hospital, China |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 October 2016 |
| Primary completion | 1 October 2019 |
| Estimated completion | 1 October 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anti-LeY-CAR-transduced T cells — full drug profile →
Conditions studied
- Myeloid Malignancies — all drugs for Myeloid Malignancies →
Sponsor
Southwest Hospital, China
Who can join
Adults 14 to 75, any sex, with Myeloid Malignancies. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Adverse Events That Are Related to Treatment
Time frame: 3 years
Determine the toxicity profile of the LeY targeted CAR T cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
Sponsor's own description
The overall purpose of this study is to explore the therapeutic effect of LeY-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of myeloid malignancies.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting cancer stem cell pathways for cancer therapy.
Yang L, Shi P, Zhao G, Xu J, et al · · 2020 · cited 1354× · PMID 32296030 · DOI 10.1038/s41392-020-0110-5 -
Engineered T Cell Therapy for Cancer in the Clinic.
Zhao L, Cao YJ. · · 2019 · cited 275× · PMID 31681259 · DOI 10.3389/fimmu.2019.02250 -
Clinical trials of CAR-T cells in China.
Liu B, Song Y, Liu D. · · 2017 · cited 55× · PMID 29058636 · DOI 10.1186/s13045-017-0535-7 -
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies.
Nasiri F, Safarzadeh Kozani P, Salem F, Mahboubi Kancha M, et al · · 2025 · cited 14× · PMID 39994651 · DOI 10.1186/s12935-025-03697-y -
The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype.
Jing Y, Liang W, Zhang L, Tang J, et al · · 2022 · cited 10× · PMID 35251985 · DOI 10.3389/fonc.2022.817971 -
Tumor-Associated Glycans as Targets for Immunotherapy: The Wistar Institute Experience/Legacy.
Thurin M. · · 2021 · cited 10× · PMID 34161162 · DOI 10.1089/mab.2021.0024 -
Cells to prevent/treat relapse following allogeneic stem cell transplantation.
Dietz AC, Wayne AS. · · 2017 · cited 10× · PMID 29222325 · DOI 10.1182/asheducation-2017.1.708 -
Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
Rotolo A, Karadimitris A, Ruella M. · · 2018 · cited 9× · PMID 29165008 · DOI 10.1080/10428194.2017.1403024
Verify or expand the search:
- PubMed search for NCT02958384
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myeloid Malignancies
Currently open trials in the same condition.
- NCT07396480 — Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic He · Phase 3 · recruiting
- NCT06930651 — A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Kn · Phase 1, PHASE2 · recruiting
- NCT06668584 — A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid M · Phase 2 · recruiting
- NCT06383572 — Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che · Phase 1, PHASE2 · recruiting
- NCT05796570 — A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine · Phase 2 · recruiting
Other Southwest Hospital, China trials
Trials by the same sponsor.
- NCT07469293 — Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke · Phase 3 · not yet recruiting
- NCT07294209 — Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients · Phase 4 · recruiting
- NCT07251374 — Osteomyelitis Multi-center Prospective Cohort Study · not yet recruiting
- NCT06894433 — Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage · NA · recruiting
- NCT06791538 — Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02958384 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Southwest Hospital, China
- Last refreshed: 20 January 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02958384.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing